These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 7564347)

  • 1. Comparison of the oral angiotensin II receptor antagonist UP 269-6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt-deplete man.
    McIntyre M; MacFadyen RJ; Meredith PA; Menard J; Brunner HR; Insuasty J; Reid JL
    J Cardiovasc Pharmacol; 1995 Jun; 25(6):994-1000. PubMed ID: 7564347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the angiotensin II antagonist UP269-6 with the angiotensin converting enzyme inhibitor enalapril in normotensive volunteers challenged with angiotensin I.
    Inglessis N; Nussberger J; Hagmann M; Hiesse-Provost O; Insuasty J; Reid J; Ménard J; Brunner HR
    J Cardiovasc Pharmacol; 1995 Jun; 25(6):986-93. PubMed ID: 7564346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men.
    McIntyre M; MacFadyen RJ; Meredith PA; Brouard R; Reid JL
    J Cardiovasc Pharmacol; 1996 Jul; 28(1):101-6. PubMed ID: 8797143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
    Nussberger J; Wuerzner G; Jensen C; Brunner HR
    Hypertension; 2002 Jan; 39(1):E1-8. PubMed ID: 11799102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man.
    Doig JK; MacFadyen RJ; Sweet CS; Lees KR; Reid JL
    J Cardiovasc Pharmacol; 1993 May; 21(5):732-8. PubMed ID: 7685442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal effects of angiotensin I-receptor blockade and angiotensin convertase inhibition in man.
    Schmitt F; Natov S; Martinez F; Lacour B; Hannedouche TP
    Clin Sci (Lond); 1996 Mar; 90(3):205-13. PubMed ID: 8777826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additive effects of losartan and enalapril on blood pressure and plasma active renin.
    Azizi M; Guyene TT; Chatellier G; Wargon M; Ménard J
    Hypertension; 1997 Feb; 29(2):634-40. PubMed ID: 9040450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of blood pressure and angiotensin responses to the renin inhibitor Ro 42-5892 and the angiotensin converting enzyme inhibitor enalapril in essential hypertension.
    van den Meiracker AH; Admiraal PJ; Derkx FH; Kleinbloesem C; Man in 't Veld AJ; van Brummelen P; Mulder P; Schalekamp MA
    J Hypertens; 1993 Aug; 11(8):831-8. PubMed ID: 8228207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SC-52458, an orally active angiotensin II-receptor antagonist: inhibition of blood pressure response to angiotensin II challenges and pharmacokinetics in normal volunteers.
    Hagmann M; Nussberger J; Naudin RB; Burns TS; Karim A; Waeber B; Brunner HR
    J Cardiovasc Pharmacol; 1997 Apr; 29(4):444-50. PubMed ID: 9156352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers.
    Goldberg MR; Tanaka W; Barchowsky A; Bradstreet TE; McCrea J; Lo MW; McWilliams EJ; Bjornsson TD
    Hypertension; 1993 May; 21(5):704-13. PubMed ID: 8491505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological demonstration of the additive effects of angiotensin-converting enzyme inhibition and angiotensin II antagonism in sodium depleted healthy subjects.
    Azizi M; Guyene TT; Chatellier G; Ménard J
    Clin Exp Hypertens; 1997; 19(5-6):937-51. PubMed ID: 9247766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patients.
    Püchler K; Nussberger J; Laeis P; Witte PU; Brunner HR
    J Hypertens; 1997 Dec; 15(12 Pt 2):1809-12. PubMed ID: 9488244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients.
    Goldberg MR; Bradstreet TE; McWilliams EJ; Tanaka WK; Lipert S; Bjornsson TD; Waldman SA; Osborne B; Pivadori L; Lewis G
    Hypertension; 1995 Jan; 25(1):37-46. PubMed ID: 7843751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differing early blood pressure and renin-angiotensin system responses to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure.
    Squire IB; MacFayden RJ; Reid JL; Devlin A; Lees KR
    J Cardiovasc Pharmacol; 1996 May; 27(5):657-66. PubMed ID: 8859935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haemodynamic and renal responses to oral losartan potassium during salt depletion or salt repletion in normal human volunteers.
    Doig JK; MacFadyen RJ; Sweet CS; Reid JL
    J Cardiovasc Pharmacol; 1995 Apr; 25(4):511-7. PubMed ID: 7596116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.
    Azizi M; Chatellier G; Guyene TT; Murieta-Geoffroy D; Ménard J
    Circulation; 1995 Aug; 92(4):825-34. PubMed ID: 7641363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in normotensive men.
    Ribstein J; Picard A; Armagnac C; Sissmann J; Mimran A
    J Cardiovasc Pharmacol; 2001 Apr; 37(4):449-60. PubMed ID: 11300658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous angiotensin II and baroreceptor dysfunction: a comparative study of losartan and enalapril in man.
    Yee KM; Struthers AD
    Br J Clin Pharmacol; 1998 Dec; 46(6):583-8. PubMed ID: 9862248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study.
    MacFadyen RJ; Lees KR; Reid JL
    Br Heart J; 1991 Sep; 66(3):206-11. PubMed ID: 1657084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enalapril in treatment of hypertension with renal artery stenosis. Changes in blood pressure, renin, angiotensin I and II, renal function, and body composition.
    Hodsman GP; Brown JJ; Cumming AM; Davies DL; East BW; Lever AF; Morton JJ; Murray GD; Robertson JI
    Am J Med; 1984 Aug; 77(2A):52-60. PubMed ID: 6089557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.